Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice

Michihiro Yoshimi, Takashige Maeyama, Mizuho Yamada, Naoki Hamada, Jyutaro Fukumoto, Tomonobu Kawaguchi, Kazuyoshi Kuwano, Yoichi Nakanishi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and objective: Erythropoietin (EPO) has recently been demonstrated to have a tissue protective role by acting as an anti-apoptotic agent in various tissues, such as brain, spinal cord, heart and kidney. The purpose of this study was to determine whether human recombinant EPO reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Methods: Bleomycin was instilled intratracheally into C57BL/6 mice. Recombinant human EPO or saline was injected intraperitoneally, daily from day 5 to day 13 after bleomycin instillation. Results: EPO receptor was expressed in bronchiolar and alveolar type II cells. At 14 days after instillation, the number of terminal uridine deoxynucleotidyl transferase nick end-labelled positive cells in the lung was decreased, and the histological degree of inflammation and fibrosis was attenuated in mice injected with EPO compared with controls. Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation. Conclusions: As it is likely that EPO protects epithelial cells from injury and apoptosis, EPO administration could be a potential therapeutic strategy for the prevention of lung injury.

Original languageEnglish
Pages (from-to)639-645
Number of pages7
JournalRespirology
Volume13
Issue number5
DOIs
Publication statusPublished - Jul 1 2008

Fingerprint

Bleomycin
Erythropoietin
Pneumonia
Epithelial Cells
Apoptosis
Erythropoietin Receptors
Alveolar Epithelial Cells
Lung
DNA Nucleotidylexotransferase
Uridine
Lung Injury
Inbred C57BL Mouse
Spinal Cord
Fibrosis
Inflammation
Kidney
Survival
Wounds and Injuries
Brain

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. / Yoshimi, Michihiro; Maeyama, Takashige; Yamada, Mizuho; Hamada, Naoki; Fukumoto, Jyutaro; Kawaguchi, Tomonobu; Kuwano, Kazuyoshi; Nakanishi, Yoichi.

In: Respirology, Vol. 13, No. 5, 01.07.2008, p. 639-645.

Research output: Contribution to journalArticle

Yoshimi, M, Maeyama, T, Yamada, M, Hamada, N, Fukumoto, J, Kawaguchi, T, Kuwano, K & Nakanishi, Y 2008, 'Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice', Respirology, vol. 13, no. 5, pp. 639-645. https://doi.org/10.1111/j.1440-1843.2008.01324.x
Yoshimi, Michihiro ; Maeyama, Takashige ; Yamada, Mizuho ; Hamada, Naoki ; Fukumoto, Jyutaro ; Kawaguchi, Tomonobu ; Kuwano, Kazuyoshi ; Nakanishi, Yoichi. / Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. In: Respirology. 2008 ; Vol. 13, No. 5. pp. 639-645.
@article{2f26d37d28f0454bb76e99665a635297,
title = "Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice",
abstract = "Background and objective: Erythropoietin (EPO) has recently been demonstrated to have a tissue protective role by acting as an anti-apoptotic agent in various tissues, such as brain, spinal cord, heart and kidney. The purpose of this study was to determine whether human recombinant EPO reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Methods: Bleomycin was instilled intratracheally into C57BL/6 mice. Recombinant human EPO or saline was injected intraperitoneally, daily from day 5 to day 13 after bleomycin instillation. Results: EPO receptor was expressed in bronchiolar and alveolar type II cells. At 14 days after instillation, the number of terminal uridine deoxynucleotidyl transferase nick end-labelled positive cells in the lung was decreased, and the histological degree of inflammation and fibrosis was attenuated in mice injected with EPO compared with controls. Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation. Conclusions: As it is likely that EPO protects epithelial cells from injury and apoptosis, EPO administration could be a potential therapeutic strategy for the prevention of lung injury.",
author = "Michihiro Yoshimi and Takashige Maeyama and Mizuho Yamada and Naoki Hamada and Jyutaro Fukumoto and Tomonobu Kawaguchi and Kazuyoshi Kuwano and Yoichi Nakanishi",
year = "2008",
month = "7",
day = "1",
doi = "10.1111/j.1440-1843.2008.01324.x",
language = "English",
volume = "13",
pages = "639--645",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice

AU - Yoshimi, Michihiro

AU - Maeyama, Takashige

AU - Yamada, Mizuho

AU - Hamada, Naoki

AU - Fukumoto, Jyutaro

AU - Kawaguchi, Tomonobu

AU - Kuwano, Kazuyoshi

AU - Nakanishi, Yoichi

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background and objective: Erythropoietin (EPO) has recently been demonstrated to have a tissue protective role by acting as an anti-apoptotic agent in various tissues, such as brain, spinal cord, heart and kidney. The purpose of this study was to determine whether human recombinant EPO reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Methods: Bleomycin was instilled intratracheally into C57BL/6 mice. Recombinant human EPO or saline was injected intraperitoneally, daily from day 5 to day 13 after bleomycin instillation. Results: EPO receptor was expressed in bronchiolar and alveolar type II cells. At 14 days after instillation, the number of terminal uridine deoxynucleotidyl transferase nick end-labelled positive cells in the lung was decreased, and the histological degree of inflammation and fibrosis was attenuated in mice injected with EPO compared with controls. Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation. Conclusions: As it is likely that EPO protects epithelial cells from injury and apoptosis, EPO administration could be a potential therapeutic strategy for the prevention of lung injury.

AB - Background and objective: Erythropoietin (EPO) has recently been demonstrated to have a tissue protective role by acting as an anti-apoptotic agent in various tissues, such as brain, spinal cord, heart and kidney. The purpose of this study was to determine whether human recombinant EPO reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Methods: Bleomycin was instilled intratracheally into C57BL/6 mice. Recombinant human EPO or saline was injected intraperitoneally, daily from day 5 to day 13 after bleomycin instillation. Results: EPO receptor was expressed in bronchiolar and alveolar type II cells. At 14 days after instillation, the number of terminal uridine deoxynucleotidyl transferase nick end-labelled positive cells in the lung was decreased, and the histological degree of inflammation and fibrosis was attenuated in mice injected with EPO compared with controls. Expression of phosphorylated Akt and Erk, which are thought to mediate the survival signalling pathway induced by EPO, tended to be increased in lung tissues from mice treated with EPO compared with those from mice treated with saline after bleomycin instillation. Conclusions: As it is likely that EPO protects epithelial cells from injury and apoptosis, EPO administration could be a potential therapeutic strategy for the prevention of lung injury.

UR - http://www.scopus.com/inward/record.url?scp=47149088797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47149088797&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2008.01324.x

DO - 10.1111/j.1440-1843.2008.01324.x

M3 - Article

C2 - 18713087

AN - SCOPUS:47149088797

VL - 13

SP - 639

EP - 645

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 5

ER -